Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 435

1.

Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival.

Shiratori Y, Ito Y, Yokosuka O, Imazeki F, Nakata R, Tanaka N, Arakawa Y, Hashimoto E, Hirota K, Yoshida H, Ohashi Y, Omata M; Tokyo-Chiba Hepatitis Research Group.

Ann Intern Med. 2005 Jan 18;142(2):105-14.

PMID:
15657158
2.

Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: a retrospective cohort study of 738 patients.

Tanaka H, Tsukuma H, Kasahara A, Hayashi N, Yoshihara H, Masuzawa M, Kanda T, Kashiwagi T, Inoue A, Kato M, Oshima A, Kinoshita Y, Kamada T.

Int J Cancer. 2000 Sep 1;87(5):741-9.

3.

Summaries for patients. Long-term effects of antiviral treatment for hepatitis C.

[No authors listed]

Ann Intern Med. 2005 Jan 18;142(2):I51. No abstract available.

PMID:
15657153
4.

Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy.

Yoshida H, Shiratori Y, Moriyama M, Arakawa Y, Ide T, Sata M, Inoue O, Yano M, Tanaka M, Fujiyama S, Nishiguchi S, Kuroki T, Imazeki F, Yokosuka O, Kinoyama S, Yamada G, Omata M.

Ann Intern Med. 1999 Aug 3;131(3):174-81.

PMID:
10428733
5.

Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis.

Veldt BJ, Heathcote EJ, Wedemeyer H, Reichen J, Hofmann WP, Zeuzem S, Manns MP, Hansen BE, Schalm SW, Janssen HL.

Ann Intern Med. 2007 Nov 20;147(10):677-84.

PMID:
18025443
6.

Interferon treatment improves survival in chronic hepatitis C patients showing biochemical as well as virological responses by preventing liver-related death.

Kasahara A, Tanaka H, Okanoue T, Imai Y, Tsubouchi H, Yoshioka K, Kawata S, Tanaka E, Hino K, Hayashi K, Tamura S, Itoh Y, Kiyosawa K, Kakumu S, Okita K, Hayashi N.

J Viral Hepat. 2004 Mar;11(2):148-56.

PMID:
14996350
7.
8.

Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus.

Shiratori Y, Shiina S, Teratani T, Imamura M, Obi S, Sato S, Koike Y, Yoshida H, Omata M.

Ann Intern Med. 2003 Feb 18;138(4):299-306.

PMID:
12585827
9.

Pegylated interferon alpha-2b plus ribavirin for naive patients with HCV-related cirrhosis.

Floreani A, Baldo V, Rizzotto ER, Carderi I, Baldovin T, Minola E.

J Clin Gastroenterol. 2008 Jul;42(6):734-7. doi: 10.1097/MCG.0b013e318046ea75.

PMID:
18285717
10.

Impact of interferon therapy on the natural history of hepatitis C virus related cirrhosis.

Gramenzi A, Andreone P, Fiorino S, Cammà C, Giunta M, Magalotti D, Cursaro C, Calabrese C, Arienti V, Rossi C, Di Febo G, Zoli M, Craxì A, Gasbarrini G, Bernardi M.

Gut. 2001 Jun;48(6):843-8.

12.

Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Osaka Hepatocellular Carcinoma Prevention Study Group.

Imai Y, Kawata S, Tamura S, Yabuuchi I, Noda S, Inada M, Maeda Y, Shirai Y, Fukuzaki T, Kaji I, Ishikawa H, Matsuda Y, Nishikawa M, Seki K, Matsuzawa Y.

Ann Intern Med. 1998 Jul 15;129(2):94-9.

PMID:
9669992
13.

Interferon therapy does not prevent hepatocellular carcinoma in HCV compensated cirrhosis.

Testino G, Ansaldi F, Andorno E, Ravetti GL, Ferro C, De Iaco F, Icardi G, Valente U.

Hepatogastroenterology. 2002 Nov-Dec;49(48):1636-8.

PMID:
12397752
14.

Antiviral therapy after non-surgical tumor ablation in patients with hepatocellular carcinoma associated with hepatitis C virus.

Hung CH, Lee CM, Wang JH, Tung HD, Chen CH, Lu SN.

J Gastroenterol Hepatol. 2005 Oct;20(10):1553-9.

PMID:
16174073
15.
16.

Prospective study of a high-intensity interferon-alpha regimen for chronic hepatitis C virus genotype 1b infection.

Toyoda H, Kumada T, Nakano S, Takeda I, Sugiyama K, Kiriyama S, Tanikawa M, Sone Y, Hisanaga Y, Hayashi K.

Hepatogastroenterology. 2002 Nov-Dec;49(48):1619-24.

PMID:
12397749
17.

Prevention of hepatocellular carcinoma and its recurrence in chronic hepatitis C patients by interferon therapy.

Omata M, Yoshida H, Shiratori Y.

Clin Gastroenterol Hepatol. 2005 Oct;3(10 Suppl 2):S141-3. Review.

PMID:
16234063
18.

Effectiveness of interferon therapy for reducing the incidence of hepatocellular carcinoma among patients with type C chronic hepatitis.

Inoue A, Tsukuma H, Oshima A, Yabuuchi T, Nakao M, Matsunaga T, Kojima J, Tanaka S.

J Epidemiol. 2000 Jul;10(4):234-40.

19.

Treatment of hepatitis C virus-related cirrhosis: a randomized, controlled trial of interferon alfa-2b versus no treatment.

Valla DC, Chevallier M, Marcellin P, Payen JL, Trepo C, Fonck M, Bourliere M, Boucher E, Miguet JP, Parlier D, Lemonnier C, Opolon P.

Hepatology. 1999 Jun;29(6):1870-5.

PMID:
10347132
20.

Sustained virological response to interferon reduces cirrhosis in chronic hepatitis C: a 1,386-patient study from Taiwan.

Huang JF, Yu ML, Lee CM, Dai CY, Hou NJ, Hsieh MY, Wang JH, Lu SN, Sheen IS, Lin SM, Chuang WL, Liaw YF.

Aliment Pharmacol Ther. 2007 May 1;25(9):1029-37.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk